StemCell Therapy

The researchers evaluated changes in DNA methylation and discovered that hibernation slows biological aging.

The big brown bat, which is the most common type of bat in the United States, has an incredibly long lifespan of up to 19 years. One of the secrets to this bats exceptional lifespan has been discovered by a recent study headed by scientists at the University of Maryland: hibernation.

Hibernation has allowed bats, and presumably other animals, to stay in northerly or very southerly regions where theres no food in the winter, said the studys senior author, UMD Biology Professor Gerald Wilkinson. Hibernators tend to live much longer than migrators. We knew that, but we didnt know if we would detect changes in epigenetic age due to hibernation.

The scientists discovered that a big brown bats epigenetic clocka biological marker of agingis extended by three-quarters of a year by hibernating for one winter. Scientists from McMaster University and the University of Waterloo, both in Ontario, Canada, were also involved in the research, which was publishedin the Proceedings of the Royal Society B.

Big brown bats can live up to 19 years. Credit: Brock and Sherri Fenton

Small tissue samples from the wings of 20 big brown bats (Eptesicus fuscus) collected across two periodswinter when they hibernated and the summer when they were activewere analyzed. The bats were housed in a research colony at McMaster University and ranged in age from less than a year to a little more than ten years.

The samples were then compared with samples obtained from the same animal during active and hibernating phases to determine changes in DNA methylation, a biological process connected to gene regulation. They revealed that certain sites in the bats genome had changes in DNA methylation, and these sites seemed to be impacting metabolism during hibernation.

Its pretty clear that the sites that decrease methylation in the winter are the ones that appear to be having an active effect, Wilkinson said. Many of the genes that are nearest to them are known to be involved in regulating metabolism, so they presumably keep metabolism down.

Some of these genes were identified as longevity genes by Wilkinson and colleagues in a previous study. According to Wilkinson, there is considerable overlap between hibernation genes and longevity genes, highlighting the relationship between hibernating and longer lifespans.

The previous study also created the first epigenetic clock for bats, which can reliably predict the age of any bat in the wild. This clock was used in the current study, allowing the researchers to show that hibernation decreases a bats epigenetic age when compared to a non-hibernating animal of the same age.

Studies like this one help to explain why bats have longer lives than would be expected for a small mammal the size of a mouse. They do, however, raise new questions.

We still dont have a very good understanding of why some bats can live a really long time and other ones dont, Wilkinson said. Weve shown that the ones that live a really long time all share the ability to hibernate or to go into torpor frequently. That seems to be a corollary, but its not sufficient because hibernating rodents dont live 20 years.

Wilkinson said he is planning a follow-up study to compare epigenetic aging in big brown bats in Canada, where they hibernate, with the same species in Florida, where they do not hibernate. In doing so, Wilkinson hopes to get an even clearer picture of the role that hibernation plays in prolonging lifespans.

Reference: Big brown bats experience slower epigenetic ageing during hibernation by Isabel R. Sullivan, Danielle M. Adams, Lucas J. S. Greville, Paul A. Faure and Gerald S. Wilkinson, 10 August 2022, Proceedings of the Royal Society B Biological Sciences.DOI: 10.1098/rspb.2022.0635

The study was funded by the American Society of Mammalogists, Sigma Xi, the University of Maryland, and the Natural Sciences and Engineering Research Council of Canada.

Read the original here:
Researchers Discover the Secret to a Small Mammals Exceptional Lifespan - SciTechDaily

Reparative techniques are vital in endodontics, andconservative measureshelp preserve the vitality of teeth and ensuring they are in good health [1,2]. Mineral trioxide aggregate(MTA) is a biocompatible compound that has found widespread usage in clinical endodontic therapy because of its low cytotoxicity and high biocompatibility and ability to stimulate new dentin development. It has been the material of paramount importance since its introduction in the 1900s [3]. Uses of MTAinclude conservative management of root fractures, perforation repair [4], pulp capping agent [5], apexification [6], retrograde filling material in apical microsurgeries [7], and revascularization measures as a coronal barrier[2]. The above procedures involve close contact with the body fluids and vital tissues, favoring physical alterations and chemical/biological communications with the material [8].

Various properties of MTA, such as physical, chemical, and biological, have been explored for extended periods, leading to discoveries of its efficient substitutes. However, improvisations are still needed to arrive at an ideal composition of the constituents of the cement. The development of a model, unflawed restorative material is still long due. To achieve thisit should possess the following characteristic properties: sealing ability, dimensional [9] and color stability [10], radio-opacity [11], insolubility when in contact with body fluids, and ability to flow with easy insertion. It should also possess biological and chemical properties such as alkaline pH, calcium (Ca) ion release, bioactivity, cell attachment, and biocompatibility[12]. Mineral trioxide aggregate owns most of the mentioned ideal properties but lacks a few, primarily color and consistency which require the most improvisations[13]. Therefore, materials with newer innovations have been launched commercially to overcome these shortcomings. This review intends to highlight the properties of MTAwith their limitations and to arrive at the developments in innovative Ca silicate-based cements (CSCs).

The main emphasis should be on the clinical facet of these CSCs, as the site of placement directly influences and determines materialproperties[14]. Mineral trioxide aggregateis a dynamic, active material as its application and placement result in constant contact of the cement with tissues and fluids. It persists for years after its insertion[15]. Its mechanism comprises Ca hydroxide leaching out of the hydrated MTA, thereby highlighting the bioactivity of MTA, which relates to the calcium ion(Ca2+) release. Placement of MTAis usually required at the site where there is a presence of blood that contaminates it, affecting the structure of the set material and reducing the Ca2+ release[6,16]. The principal limitations of MTA include a delayed setting time, lack of good handling features, and the disadvantage of discoloration.

Also, the contact of MTAwith blood can alter the color of the material andinterferes with radiopacity over time[17]. Moisture drastically affects the time of setting and the material solubility. Excessive water results in increased solubility and setting time of MTA. During the setting process of MTA, it chemically interacts with tissues making the environment alkaline by releasing Ca2+ ions, which are linked to the development of portlandite (calcium hydroxide) by tricalcium silicate (C3S) and dicalcium silicate (C2S)[18].

In vitro studies done with MTAAngelus and ProRoot MTArevealed Ca2+ ion discharge andalkalization of the environment when the material was submerged in water. The release of Ca2+ ions was detected by von Kossa staining of subcutaneous tissues of rats[19]. These properties lead to mineralization on the surface of the set MTAin pulpotomy procedures. This is proven by studies where hard tissue was formed apically in a dog's teeth which were seen along with the sealing ability in cases of furcation perforation[20].

In an in vivo study by Han et al., the odontogenic potential of osteostatin (OST) and the combined effect with bioceramic materials on human dental pulp stem cells (hDPCs) were investigated, and it was discovered that the combination of MTAand OSThad a synergistic odontogenic differentiation of hDPCs when compared to MTAalone[21]. Micro-CT research demonstrated that OSTwith ProRoot MTAgroups formed more mineralized dentin bridges[22].

During dental operations, the most significant property of observation is color. Tooth discoloration damages the tooth's aesthetic appearance. The complex response between filling materials and coronal dentine of the pulp chamber, which modifies the crowns appearance, is a significant cause of tooth discoloration.

Initially, when developed, MTAhad a grey color owing to the presence of tetra Ca aluminoferrite, making it unsuitable for its application on anterior teeth. Therefore, this led to the establishment of white MTA which is devoid of iron to prevent the discoloration of the tooth. On the contrary, many studies have proven the alteration in color even with white MTA[23]. The composition of white MTAincludes C2S and C3S silicate with 20% of bismuth oxide. According to reports, the amount of bismuth oxide added to MTA to increase its radio-opacity was only 8.4% in the set material compared to 21.6% in the unset material [8]. When reduction of bismuth oxide occurs along with its contact with the tooth structure, it alters the color of the cement and the color of the adjacent tooth structure. The cause of color change has been identified and attributed to the loss of stability of the bismuth oxide molecules, which occurs as they come in close contact with a potent oxidizing agent[24]. Hence, it is suggested that if the radiopacifier agent is changed, it can help prevent the discoloration of the tooth. Two materials have been lab tested to replace bismuth oxide, namely zirconium oxide and Ca tungstate. However, large amounts are necessary to match the radiopacity ofbismuth oxide. Adding such large amounts can negatively impact the chemical and physical properties of the dental material[25]. Newer CSCs such as Biodentine and Bioceramic (BC) sealer, and MTA high plasticity (HP) can alter the radiopacifier agent into Ca tungstate or zirconium oxide.These constituents caused no alteration in color[26]. The second substitute is the addition of 5% zinc oxide (ZnO) to MTAas this ZnO converts bismuth oxide into bismite, a product that helps prevent the change of color[10].

There is a difference in opinion regarding the consistency of MTA. The ratio of powder to water is essential as increasing the quantity of water reduces radiopacity. The particle size is vital here as the newer advances in silicate types of cement have been developed using nanoparticles of Ca silicate (CS). The BCsealer and biosealer containing nanoparticles of CSwith the addition of a polymer help in easy handling and givean ideal material consistency. Adding propylene glycol to MTAcaused no interference in its biological properties. Propylene glycol was tested using different ratios for chemical and physical properties in which 20% propylene glycol was mixed with 80% distilled H2O,which led to efficient handling of MTA, pH, enhanced Ca release, and flowability. However, it caused slight alterations in setting time[27]. Few studies have proven that propylene glycol caused improved adhesion of MTA.

The advances which lead to enhanced flow ability comprise MTA HP, MTA Flow, Biodentine (Septodont, Saint-Maur-des-Fosss, France),and ones having ceramic complexes incorporated with Biodentine, EndoSequence (Brasseler, Savannah, GA, USA), and BioAggregate (Verio Dental Co. Ltd., Vancouver, Canada).

In 2009, Biodentine, a Ca silicate-based product, was introduced. Zirconium oxide is used instead of bismuth oxide in Biodentine. Zirconium oxide is a bioinert substance with good mechanical qualities & corrosion resistance. Dettwiler et al. 2016 observed this closely in an experiment [28]. Biodentine had a minor discoloration, higher solubility than MTA, and a significantly faster setting time. In as little as 12 minutes, Biodentine can begin to block blood components, becoming denser and packed as it sets. As a result, erythrocyte penetration is reduced, resulting in less tooth discoloration during the pulpotomy operation. Because it comprises more powder with a water-reducing agent and less porosity, the Biodentine material significantly impacts various factors such as absorption, strength, and density[29]. Biodentine and zinc oxide-eugenolcement (IRM) had the lowest level or degree of porosity and the least amount of tooth discoloration, according to Camilleri et al. in 2013[14].

Endosequence root repair material (ERRM), is available as a premixed putty with uniform consistency and easier handling and application. According to the manufacturer, the setting begins with the presence of moisture in the dentinal tubules. When pulp cells were exposed to ERRMor ProRoot MTA, survival and proliferation were identical, suggesting that it could be a good choice for pulp capping treatments[30].

BioAggregate (BA)contains monobasic Ca phosphate, amorphous silicon dioxide, and tantalum pentoxide for radiopacity. And due to its Ca phosphate content,it is classified as a biphasic material (one that contains two cementitious ingredients)[31]. It is more acid resistant than MTA, has a longer-lasting strengthening effect on weaker teeth, and has a lower risk of discoloration[31]. In the treatment of immature teeth, it has demonstrated similar results as MTA.

The main composition of MTAis CS. Bioactivity is one characteristic feature of Ca silicate-based types of cement[27]. Newer CS-based restorative types of cement have been launched to substitute bismuth oxide like Biodentine, Neo MTAPlus (Avalon Biomed Inc.Bradenton, FL, USA), and MTARepair HP (Angelus, Londrina, PR, Brazil). Others include MTAFillapex (Angelus, Londrina, PR, Brazil), Neo MTAPlus, iRoot SP (Innovative BioCreamix Inc, Vancouver, BC, Canada), and TotalFill BC (Davis Schottlander & Davis Ltd. Letchworth, Herts, UK) sealer.

The MTAFillapex cement comes in a paste-paste form which comprises salicylate and natural resin, infused silica nanoparticles, MTA, and Ca tungstate which acts as radiopacifier.There is a newly introduced C2S silicate-based system with a powder-gel formulation named Neo MTA, a remarkable restorative and endodontic cement that can be used with various proportions of powder gel ratios. The composition of iRoot SPis zirconium oxide, CS, Ca phosphate, Ca hydroxide, and thickening agents, which are commercially accessible and is used as a root canal filling material. On the other hand, EndoSequence BC sealer and TotalFill BC sealer comprises zirconium oxide, CS, monobasic Caphosphate, Ca hydroxide, and thickening agents. This latter cement is advantageous as it sets in the presence of dentin moisture and hence was used as canal filling material.

A study on iRoot SPendodontic cement advocated the absence of cytotoxicity to fibroblasts when tested in rats[32]. Alternative research by Zoufan et al., checked the cell compatibility of iRoot SPcement at two stages: after the cement was freshly mixed, and after the cement had been set[33]. It was found that this cement had a greater induction capacity of osteoblastic differentiation and decreased inflammatory response with the periodontal ligament cells compared to Sealapex[34].

The MTAand iRoot SPtypes of cement have been proven to induce differentiation in osteoblastic cells in the tooth germ. The iRoot SPsignificantly showed its antibacterial activity against Enterococcus faecalis[35]. Zhu et al. found evidence of the ability of BioAggregate cement to promote cell adhesion to each other, migration, and fixation of human dental pulp cells, thus proving its cytocompatibility[36].

Bioceramic endodontic cement-like Endosequence BC sealerhas displayed promoting superior cell viability than AHPlus sealer and also offered an increased level of biocompatibility when compared with newly handled AHPlus and MTAFillapex,when freshly mixed and after the setting. Bioceramic sealer has shown satisfactory adhesion to fibroblasts[37]. Upon contact with the biological solution, discharge of Ca and development of the Ca phosphate phase was seen. Antibacterial activity against biofilm formed on dentin was greater when Endosequence BC sealer was used along with 5% sodium hypochlorite than the irrigation solution alone[38]. In a study using confocal laser microscopy, Wang et al. concluded that in 30 days, a BioCeramic sealer could eliminate 45% of E. faecalis from the dentinal tubules, indicating the antibacterial action of theBioceramic sealer lasted even after the setting of the material [39]. Total fill BioCeramic sealer is identical to Endosequence BC sealer. The only difference is that the former promotes extensively higher proliferation of cells compared to AHPlus and MTA Fillapex.The structure of cells embedded on Total Fill BioCeramic Sealer and AHPlus showed similar physiognomies, along with the assembly of the extracellular matrix. In contrast, limited fixation of cells was seen on discs of MTAFillapex, with decreased number of cells on the material surface[40].

The MTA Angelus, MTA HP, and Neo MTA P presented viability of cells and a higher degree of cellular proliferation along with adhesion. Using HDPCs, greater viability was seen with MTAplus compared to MTAFillapex and Fillcanal; increased phosphates activity was observed with MTAPlus[41,42]. No cytotoxic effect was seen with Neo MTAPlus, MTAAngelus, and experimental C3S silicate-based cement with tantalum oxide (TSC/Ta205). According to the alizarin red assay, the three materials were proven to induce the formation of mineralized nodules; on the other hand, NEOproduced a considerable quantity of mineralized nodules compared to MTAand TSC[43]. Following subcutaneous implantation in rats, histological analysis established that MTA HPshowed similar biomineralization and biocompatibility potentials to MTA Angelus[43]. The MTAAngelus and MTAPlus showed no presence of cytotoxicity and induced mineralized nodule formation. When PCR was used, the authors concluded that when HDCPs were exposed to extract the two types of cement, it increased the expression of osteogenic markers of the cell[44].

According to Petrovic et al., materials based on CSand hydroxyapatite (HA-CS) showed a superior grade of biocompatibility compared to MTAAngelus [45]. Also, improved outcomes were seen for CS and HA-CS when subcutaneous implants were placed in rats. In the assessment of the biocompatibility of three Ca silicate-based types of cement, which include Bioroot BC sealer (BR), Endoseal MTA(ES) & Nanoceramic sealer (NCS), along with human periodontal ligaments stem cells (hPDLSCs), BRand NCSshowed superior cytocompatibility as compared to ES[46]. The BCsealer was proficient in hindering the release of immunoreactive calcitonin gene-related peptide (iCGRP) from trigeminal ganglion neurons and excellent biocompatibility, thereby reducing the symptomatology level after extravasation of the cement in ongoing treatment[47].

In a study by Almedia et al., a comparison of physiochemical and biological properties of already mixed Ca silicate-based endo sealers with routinely used root canal (RC) filling materials by thoroughly revising lab investigations [48]. Calcium silicate-based endodontic sealers followthe ISO 6876:2012 standard for most physicochemical properties, except solubility. The target sealers depicted commendatory biological traits in comparison to conventional sealers. Despite failing to test the target premixed Ca silicate-based sealers in long-term experimental clinical trials, they presented with good physicochemical and biological traits in vitro.

Visit link:
A Breakthrough in the Era of Calcium Silicate-Based Cements: A Critical Review - Cureus

Source: Northwestern University

Cells are the building blocks of tissue, and tissues are the basic unit of function in the body. Generally, groups of cells make and secrete their own support structures, called extra-cellular matrix. This matrix, or scaffold, does more than just support the cells; it also acts as a relay station for various signaling molecules. Thus, cells receive messages from many sources that become available from the local environment. Each signal can start a chain of responses that determine what happens to the cell. By understanding how individual cells respond to signals, interact with their environment, and organize into tissues and organisms, researchers have been able to manipulate these processes to mend damaged tissues or even create new ones.

The process often begins with building a scaffold from a wide set of possible sources, from proteins to plastics. Once scaffolds are created, cells with or without a cocktail of growth factors can be introduced. If the environment is right, a tissue develops. In some cases, the cells, scaffolds, and growth factors are all mixed together at once, allowing the tissue to self-assemble.

Another method to create new tissue uses an existing scaffold. The cells of a donor organ are stripped and the remaining collagen scaffold is used to grow new tissue. This process has been used to bioengineer heart, liver, lung, and kidney tissue. This approach holds great promise for using scaffolding from human tissue discarded during surgery and combining it with a patients own cells to make customized organs that would not be rejected by the immune system.

View original post here:
Tissue Engineering and Regenerative Medicine - National Institute of ...

OPTIMAL Pain & Regenerative Medicine focuses on treating patients through restorative and pain management solutions. We offer state of the art biologic treatments that have changed the way medicine is practiced today. Our practice specializes in the treatment of neck and back pain, arthritis, neuropathy, diseases, headaches, joint and soft-tissue injuries and sports related injuries.

Dr. Scott Berlin and Dr. Michael Phillips of OPTIMAL Pain & Regenerative Medicine strive to be at the forefront in providing cutting edge pain management and regenerative medicine options to the Dallas-Ft. Worth metroplex. As board certified anesthesiologists, their collective expertise includes a full range of innovative treatment options. No matter what your stage of life, OPTIMAL delivers comprehensive, current and most importantly, compassionate medical care.

To date, it is estimated that over 116 million American adults are affected by some degree of chronic pain. Pain management is important for patients who are suffering from acute, chronic and cancer pain. Pain management includes injection/interventional therapy, implantable therapies, physical therapy,medication managementand other suitable treatment options.

Regenerative medicine offers a solution to patients who have conditions that seem beyond repair. Regenerative medicine is a process of replacing the bodys owns cells, tissues or organs to restore normal function. OPTIMAL specializes in minimally invasive bone marrow aspirate concentrate (BMAC), a stem cell therapy for back pain, as well as platelet rich plasma therapy (PRP) for joints or soft tissue injuries.

To get to learn more about our practice please review our physician profiles and patient education.

Go here to read the rest:
Pain Management & Regenerative Medicine Specialists DFW

The project for the development of the International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt is moving forward.

Recently, the North African countrys Ministry of Defense awarded a management and supervision consultancy services contract for the project. The contract was awarded to Hill International an American construction consulting firm that provides program, project, and construction management services.

International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt will feature three components categorized as facilities. These will be the animal welfare facility, the bioreactor facility, and the research facility. Moreover, center staff will have the opportunity of using the new facilities. The staff will have the liberty of conducting basic and preclinical clinical trials with stem cells.

The healthcare project represents the latest effort to enrich the countrys healthcare sector. It aims to leverage the therapeutic potential of stems to develop. The development of stem cells will contribute to a major advance in regenerative medicine.Moreover, it would be a great opportunity to not just promote health and welfare in Egypt, but to the whole world as well.

Also Read:Contracts signed for UC Development projects in NAC, Egypt

The International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt will work in cooperation and together with industrial, non-governmental, academic as well as governmental institutions.

The CEO of Hill International spoke about the project. Raouf Ghali affirtmed that the firm will make use of its expertise to ensure the project is realized as planned. Moreover, the CEO added that the company is proud of the projects progress as it will be of great impact on the country.

Hill International boasts over 3,200 professionals in approximately 100 offices worldwide. Impressively, the ENgineering New-Record magazine ranks the firm as one of the largest construction management firms.

If you need more information on this project. Current status, project team contacts etc. Please contact us

(Note this is a premium service)

Read more from the original source:
International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt - Construction Review

Media Advisory

Wednesday, August 31, 2022

At the National Institutes of Health, a surgical team successfully implanted a patch of tissue made from patient cells with the goal of treating advanced dry age-related macular degeneration (AMD), also known as geographic atrophy. Dry AMD is a leading cause of vision loss among older Americans and currently has no treatment.

The patient received the therapy as part of a clinical trial that is the first in the United States to use replacement tissues from patient-derived induced pluripotent stem (iPS) cells. The surgery was performed by Amir H. Kashani, M.D., Ph.D., associate professor of ophthalmology, Wilmer Eye Institute, Johns Hopkins School of Medicine with assistance by Shilpa Kodati, M.D., staff clinician, NEI. The procedure was performed at the NIH Clinical Center in Bethesda, Maryland, under a phase 1/2a clinical trial to determine the therapys safety.

This iPS cell derived therapy was developed by the Ocular and Stem Cell Translational Research Section team led by Kapil Bharti, Ph.D., senior investigator at the National Eye Institute (NEI), part of NIH, in collaboration with FUJIFILM Cellular Dynamics Inc., and Opsis Therapeutics, based in Madison, Wisconsin. Safety and efficacy of this cell therapy was tested by the NEI preclinical team. Clinical-grade manufacturing of this cell therapy was performed at the Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, NIH.

This surgery is the culmination of 10 years of research and development at the NEI. In the NIH lab, the patients blood cells were converted to iPS cells, which can become almost any type of cell in the body. In this case, they were programmed to become retinal pigment epithelial (RPE) cells, the type of cell that degenerates in the advanced forms of dry AMD. RPE cells nourish and support light-sensing photoreceptors in the retina. In AMD, the loss of RPE leads to the loss of photoreceptors, which causes vision loss. This work was supported by the NIH Common Fund and NEI Intramural funding.

Kapil Bharti, Ph.D., senior investigator, Ocular and Stem Cell Translational Research Section, NEI

Brian Brooks, M.D., Ph.D., chief, Ophthalmic Genetics and Visual Function Branch, NEI

To schedule interviews with Drs. Bharti and Brooks, contact NEI at neinews@nei.nih.gov

NIH launches first U.S. clinical trial of patient-derived stem cell therapy to replace and repair dying cells in retina (News release)

NIH researchers rescue photoreceptors, prevent blindness in animal models of retinal degeneration (News release)

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated with Age-Related Macular Degeneration (Clinical trial information)

About the NEI: NEI leads the federal governments efforts to eliminate vision loss and improve quality of life through vision researchdriving innovation, fostering collaboration, expanding the vision workforce, and educating the public and key stakeholders. NEI supports basic and clinical science programs to develop sight-saving treatments and to broaden opportunities for people with vision impairment. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Excerpt from:
First U.S. patient receives autologous stem cell therapy to treat dry AMD - National Institutes of Health (.gov)

Global regenerative medicine market was valued at USD 27.29 Billion in 2020. It is expected to increase at a compound annual rate (CAGR of 11.27%) between 2021 and 2027. Tissue Engineering is the segment expected to see the greatest growth in the Global Regenerative Medicine Market. Biomaterials currently hold the largest market share in global regenerative medicine.

Regenerative medicine has the potential to treat chronic, incurable diseases such as Alzheimers disease, Parkinsons disease, diabetes, and other conditions. The Alliance for Regenerative Medicine estimates that around 1,028 clinical trials in regenerative medicine are currently underway. In 2018, regenerative medicine was funded with a total of USD 13.3 billion in global financing. The forecast period will see a significant increase in investment by market leaders in research and development of regenerative medicines.

Driving Factors

Growing prevalence of chronic diseases, genetic disorders, and cancer

Over the past few decades, the prevalence and incidence of chronic diseases like CVD, cancer and diabetes has increased dramatically around the world. Diabetes and obesity can lead to an increase in the number and complexity of wounds like infections, ulcerations (leg and foot ulcers), as well as surgical wounds. These will need treatment and may result in exorbitant medical costs.

Ask For PDF Sample Report Here: https://market.us/report/regenerative-medicine-market/request-sample/

Restraining Factors

High cost of cell and gene therapies

The cell and gene therapies represent significant medical and scientific advancements for patients with serious and terminal illnesses. These therapies are changing the way diseases are treated and could even be cured. Injectable therapies will enable doctors and other medical professionals to infuse cells/genes through injectable methods, thereby avoiding multiple surgeries and the need for a number of drugs. Although these therapies can be life-saving and more effective than traditional treatments, demand is lower than anticipated. This is due to the high cost of these therapies as well as difficulties in obtaining coverage and reimbursements for them.

Market Key Trends

Recent development

Do you have any questions? Consult about the report at: https://market.us/report/regenerative-medicine-market/#inquiry

Key Companies

Segmentation

Type

Application

Frequently Asked Questions About This Report

Explore our related report:

About Market.us

Market.US (Powered by Prudour Private Limited) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report providing firm.

Contact Details:

Global Business Development Team Market.us

Address: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States

Phone: +1 718 618 4351 (International), Phone: +91 78878 22626 (Asia)

Email: [emailprotected]

Read the original post:
Regenerative Medicine Market to Garner Bursting Revenues [+USD 27.29 Billion] with Top Growing Companies During 2022-2029 - eTurboNews | eTN

Immusoft is heading into the clinic with what it claims is the first engineered B cell gene therapy cleared for in-human study, the company announced Thursday.

The Seattle-based company reported it has received clearance from the FDA to initiate a Phase I study assessing ISP-001 for the treatment of Mucopolysaccharidosis type I. MPS I is a rare lysosomal storage disorder characterized by an abnormal build-up of glycosaminoglycans in the body. Immusoft aims to improve treatment of MPS 1, also known as Hurler Syndrome, with its Immune System Programming platform that uses B cells as re-dosable biofactories for therapeutic protein delivery.

Immusoft stated its platform has been designed to circumvent both immunogenicity associated with virus-delivered gene therapy, as well as chemotherapy preconditioning associated with stem cell-mediated gene therapy. Additionally, the ISP platform has been designed to enable durable therapeutic delivery and the potential to re-dose patients if necessary.

The FDA has granted ISP-001 Orphan Drug designation and Rare Pediatric Disease designation for MPS 1. The Phase I study is expected to launch later this year, the company announced.

Sean Ainsworth, chairman and CEO of Immusoft, expressed excitement over the IND clearance. He called it a huge achievement for the company and a historic moment in the field of cell and gene therapies. Current adeno-associated virus therapies and lentiviral therapies have some safety concerns. The delivery mechanism in those therapies can trigger an immune response in patients, which can limit efficacy. Stem cell treatments also have some drawbacks in some patients.

Ainsworth told BioSpacethat the companys B cell approach has been designed to overcome some of the issues that were seen in other gene therapy modalities. Building on advances made in other cell therapeutic approaches such as CAR-T therapies, Ainsworth said the company is pioneering a gene therapy approach that allows for a durable therapeutic and the potential to re-dose patients.

Our engineered B cell approach is a completely novel modality that opens potential new avenues for treating intractable diseases. Having our lead program cleared to proceed into the clinic - the first B cell approach in the clinic - broadens the potential for our platform and pipeline as we advance other programs to first-in-human studies, Ainsworth said in an email this morning.

B Cell-Focused Competition

Immusoft isnt the only company focused on the development of B cell therapies. Others include Be Biopharma and Walking Fish Therapeutics.

Paul Orchard, a professor in the division of pediatric bone marrow transplantation at the University of Minnesota Medical Center, noted that a non-viral delivery method such as ISP-001 holds promise for the treatment of some diseases, such as MPS I. He said there is a clear need for new treatments for MPS I, as current options are not curative and significant disease-related morbidity still exists.

Although there is no cure for MPS I, there are several treatment options, including hematopoietic stem cell transplant and BioMarins Aldurazyme (laronidase), an enzyme replacement therapy. However, enzyme replacement therapies require frequent infusions, which affect quality of life. Immusoft hopes its therapeutic will mitigate the need for frequent dosing and improve patient outcomes.

Other companies developing therapies for MPS I include Orchard Therapeutics and REGENXBIO.

Beyond MPS I, Immusoft has partnered with the California Institute for Regenerative Medicine on the development of a therapy for MPS II, a carbohydrate metabolism disorder.

Read the rest here:
Immusoft Takes First-Ever Engineered B Cell Therapy into Clinic - BioSpace

Photo courtesy of Mayo

With the promise of regenerative medicine comes the risk of widening health care disparities. Sometimes the newest discoveries, such as regenerative interventions, are out of reach for people in diverse ethnic or socioeconomic groups or they may not understand or trust new options for healing.

Mayo Clinicis trying to overcome those barriers by launching community outreach and a bioethics study aimed at improving access to regenerative medicine among underserved groups.

Regenerative medicine sometimes could look like a science fiction movie. It is important to learn from the community about how things could be better explained to them or how we can erase any doubts that they have about what we do, says Jorge Mallea, M.D., a pulmonologist at Mayo Clinic in Florida. Listening to their concerns, and explaining what we know, the things still we dont have solutions for, and what we are trying to accomplish could improve understanding and engagement.

Regenerative medicine is an emerging field of practice that is shifting the focus of health care from fighting disease to rebuilding health, with an emphasis on repairing, replacing or restoring diseased cells and tissues. Mayo ClinicsCenter for Regenerative Medicineis at the vanguard of this movement, supporting the concept of regeneration for all. Dr. Mallea chairs the centers Equity, Inclusion and Diversity Advisory Committee.

More diverse clinical trials

To ensure that regenerative therapies go beyond selected or priority groups, Mayo Clinic is expanding the recruitment for clinical trials to include more diversity in race, age and socioeconomic status. For example, a dermatology study in Rochester is exploring how certain regenerative interventions might affect ethnic groups with different skin tones.

We want to learn more about diverse groups to ensure the therapies we apply would work for people of different genders, races and genetics, says Dr. Mallea. Its important to have representation from diverse groups. We could learn in our clinical trials that certain groups need different doses or distinct ways of applying the interventions.

In other research,Zubin Master, Ph.D., a bioethicist in Mayo ClinicsBiomedical Ethics Research Program, is leading a bioethics study that seeks to understand possible economic, social and ethnic barriers toplatelet-rich plasma platelets spun from a persons own blood and containing growth factors as an orthobiologic treatment for kneeosteoarthritis. Platelet-rich plasma is a new regenerative intervention that shows healing potential. However, the Food and Drug Administration has not yet approved it. Therefore, patients must pay out of pocket for it.

Mohamed Addani, aMayo Clinic Graduate School of Biomedical Sciencesstudent within Dr. Masters team, will interview patients across Mayo Clinic who choose platelet-rich plasma as an intervention for knee osteoarthritis and those who opt instead for standard care. The team will compare those responses to a more demographically diverse group of patients whove made similar care choices at Detroit Medical Center. Researchers will examine race, ethnicity, socioeconomic and demographic variables, beliefs, attitudes, and understanding of regenerative medicine.

This study will provide the first scientifically based data on whether health disparities exist among patients seeking next-generation regenerative interventions such as platelet-rich plasma, says Dr. Master. The results will give us the unique opportunity to identify factors that are creating barriers to regenerative care and proactively address ways to overcome them.

The project seeks to improve access and make regenerative medicine more equitable among diverse and underserved groups.

Showcasing the cool stuff

Attracting a more diverse pool of regenerative medicine scientists and practitioners is another strategy to boost inclusivity. Mayo Clinic is taking regenerative medicine on the road to high schools and colleges near its destination locations in Arizona, Florida and Minnesota, showcasing what Dr. Mallea describes as the cool stuff in research and development. The hope is that it might inspire students, particularly those from underrepresented and disadvantaged communities, to consider a career in regenerative medicine.

We are sharing examples of our research, such as bioprinting of organs and developing new medicines from living organisms like cells to fight different diseases and cancers, says Dr. Mallea. We hope to plant a seed in their minds that regenerative medicine holds promise not only as a future therapy, but also a future career.

In addition, Mayo is using the Community Scientist Program to open its doors to scientists from the community who want to learn more. This program pairs community scientists with regenerative medicine researchers. Mayo hopes these strategies will improve the interaction and understanding needed to ensure access to new regenerative therapies as they are introduced in the practice.

Envision yourself working for a global leader in an industry fueled by innovation and growth. Mayo Clinic has opportunities for you. Join us at Floridas No. 1 hospital by visiting https://jobs.mayoclinic.org/. For more information on health care topics please visit Mayo Clinic Jacksonville at mayoclinic.org.

See original here:
Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville - Jacksonville Free Press

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced that members of its management team will participate in investor and medical conferences later this month.

A live webcast of the presentations from the HC Wainwright and Baird conferences can be accessed on the Investors & Media section of Frequencys website. A replay will be posted following the event.

About Frequency Therapeutics

Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore human function first in hearing loss and then in multiple sclerosis by developing therapeutics that activate a persons innate regenerative potential within the body through the activation of progenitor cells. Frequencys hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for sensorineural hearing loss. Frequency is also advancing a pre-clinical program for remyelination in multiple sclerosis.

Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, and the Scripps Research Institute.

For more information, visit http://www.frequencytx.com and follow Frequency on Twitter @Frequencytx.

Read more:
Frequency Therapeutics to Participate in September Investor and Medical Conferences - Business Wire

VIKEN, Sweden, Aug. 31, 2022 /PRNewswire/ -- TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body's ability to self-repair and regenerate, today announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the unique broad spectrum mechanism of action of TikoMed's ILB neuroprotective drug platform. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and restored cellular homeostasis and function by releasing heparin-binding growth factors. TikoMed believes this approach to enhancing the body's self-repair and regeneration capabilities has the potential to transform current cell and gene therapy paradigms.

"These studies show that ILB releases, re-distributes and modulates the bioactivity of endogeneous heparin-binding growth factors that target disease compromised nervous tissues to initiate a cascade of transcriptional, metabolic and immunological effects that play a key role in controlling glutamate toxicity, normalising tissue bioenergetics, and resolving inflammation to improve tissue function. ILB's unique mechanism of action supports the potential to treat various acute and chronic neurodegenerative disease, including sTBI and ALS," said Ann Logan, Scientific Director at Axolotl Consulting and, Professor of Regenerative Medicine at the University of Warwick.

In summary, the studies provided evidence that ILB has a profound therapeutic effect on molecular and cellular dysfunctions causing neurodegenerative diseases. Gene expression analysis demonstrated substantial similarities in the functional dysregulation induced by severe traumatic brain injury (sTBI) and various human neurodegenerative conditions including ALS. Changes in gene expression following ILB treatment supported a cascading beneficial effect of ILB on growth factor activation resulting in the observed therapeutic effect. The transcriptional signature after ILB treatment is relevant to cell survival, inflammation, glutamate signalling, metabolism and synaptogenesis, and is consistent with the activation of neuroprotective growth factors. The ability of ILB to elevate circulating levels of heparin-binding growth factors in animal models and humans also supports its neuroprotective and regenerative effects in vivo.

Story continues

"ILB is currently being in development both as a therapeutic and as an enabling technology for advanced therapies, and this peer-reviewed research indicates even wider potential. We have initiated development programs for Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI) and islet cell transplantation and will now consider broader use across a wider range of diseases," said Anders Kristensson, CEO of TikoMed.

Contact: info@tikomed.com or +46 42 23 84 40

Media:

International: Richard Hayhurst richard@rhapr.eu or +44 7711 821527

Nordics: Ola Bjorkman ola.bjorkman@letemknow.se or +46 70 245 7497

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/tikomed/r/tikomed-s-ilb--mobilizes-and-modulates-key-growth-factors-that-trigger-a-cascade-of-neuroprotective-,c3623306

SOURCE Tikomed

Go here to see the original:
TikoMed's ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all...

A new study led by the University of Oviedo in Spain has unlocked the genetic code of the immortal jellyfish, an animal capable of repeatedly reverting into a juvenile state after sexual reproduction. The experts hope that better understanding the factors leading to this creatures unique longevity could offer new perspectives on human aging.

Although many species of jellyfish have some capacity to reverse aging and revert to a larval state, most of them lose this ability once they reach sexual maturity. However, Turritopsis dohrnii appears to be the only known species able to repeatedly revert back into a larval stage even after sexual reproduction. According to the experts, the immortal jellyfish uses this superpower to avoid predators, allowing it to revert to a cyst which turns into a polyp attached to the seafloor when threaten by other animals. Once the threat is gone, the creature starts to mature once again.

To better understand what makes T. dohrnii special, the scientists sequenced its genome and compared it to that of Turritopsis rubra, a close genetic relative which lacks the capacity to rejuvenate after reaching sexual maturity. The analysis revealed that T. dohrnii had twice as many copies of the genes associated with DNA repair and protection, which helps producing greater amounts of protective and repairing proteins. Moreover, this jellyfish also had unique mutations which stunted cell division and prevented telomeres (chromosomes protective caps) from deteriorating.

Our results suggest that gene amplification and point variants unique ofT. dohrniicould affect its replicative efficiency, as well as DNA repair and telomere maintenance activity, which may be pivotal processes for cell rejuvenation and proliferation, the study authors explained.

In addition, expansions and sequence variations of genes associated with DNA repair, mitochondrial dysfunction and intercellular communication could increase its capacity to maintain redox environment and reduce cellular damage during stress events.

These findings could inspire developments in regenerative medicine and provide insights into age-related diseases such as cancer or neurodegeneration. However, as Monty Graham, a jellyfish expert and director of the Florida Institute of Oceanography put it, we cant look at it as, hey, we are going to harvest these jellyfish and turn them into a skin cream. Instead, exploring such gene variants in T. dhornii and other animals including humans could shed more light on the nature of aging, and help scientists slowly build an arsenal to combat its most unwanted effects.

The study is published in the journal Proceedings of the National Academy of Sciences.

By Andrei Ionescu, Earth.com Staff Writer

Go here to read the rest:
Can the immortal jellyfish teach us how to reverse aging? - Earth.com

MILPITAS, Calif.--(BUSINESS WIRE)--Applied StemCell, Inc. (ASC), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today announced the expansion of its Current Good Manufacturing (cGMP) facility. ASC has successfully carried out cell banking and product manufacturing projects in its current cGMP suite and is now set on building 4 additional cGMP cleanrooms, cryo-storage space, and a process development and QC/QA space. The expansion of the facility will increase its cell banking and cell product manufacturing capacity and allow ASCs team of experts to work simultaneously on multiple manufacturing projects such as iPSC generation, gene editing, differentiation, and cell bank manufacturing for safe and efficacious therapeutic products.

We are very excited to move forward with the expansion of our cGMP facility, said Dr. David Lee, Ph.D., Head of GMP and Quality. Our team has been working closely with our clients to ensure delivery of high-quality clinical grade products. We thank our customers for their support and trust. With the addition of 4 cGMP cleanrooms, we will be able to assist a greater number of researchers focused on cell and gene therapy.

President and CEO, Dr. Ruby Yanru Chen-Tsai, Ph.D. stated, We are committed to becoming a CDMO leader to support regenerative medicine and cell/gene therapy development and manufacturing. We aim to expand our bio-manufacturing capacity to meet the fast-growing demand in the cell and gene therapy industry. Our unique platform of GMP-grade allogeneic iPSC and TARGATTTM gene editing technology provides our partners great advantages, including shorter manufacturing timelines, non-viral gene editing, and genomic stability and safety.

Construction will begin within the next month, and the company has already begun the staff hiring process. ASC hopes to have the expansion completed and a team built that will be ready to take on as much as 4 times more new projects early next year.

About Applied StemCell, Inc.

ASC has a Drug Manufacturing License from the California Department of Public Health, Food and Drug Branch (FDB). It has a Quality Management System (ISO 13485 certified) and established cGMP-compliant protocols for cell banking and manufacturing, iPSC generation, genome editing, iPSC differentiation, and cell product manufacturing. With over 13 years of gene-editing and stem cell expertise, ASC offers comprehensive and customized cell and gene CRO/CDMO solutions. Its core iPSC and genome editing (CRISPR and TARGATTTM) technologies, facilitate site-specific, large cargo (up to 20kb) transgene integration and the development of allogenic cell products.

More here:
Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire

CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced the appointment of Rainer Boehm as an independent director to its Board of Directors. Mr. Boehm will serve on Omega's audit and compensation committees.

"Rainer's growth-oriented perspective and global strategic management experience will be invaluable to Omega in this next phase of the Company's trajectory," said Noubar Afeyan, Ph.D., Co-founder and Chairman of the Board for Omega Therapeutics and Founder and Chief Executive Officer of Flagship Pioneering. "I look forward to working closely with him as Omega continues to advance its clinical pipeline and demonstrate the broad capabilities of its pioneering drug development platform."

"We are thrilled to welcome Rainer to our Board and look forward to leveraging his significant drug development expertise, strategic thought-leadership and executive management skills as we work to advance our new class of programmable epigenetic medicines," said Mahesh Karande, President and Chief Executive Officer of Omega. "Rainer is a recognized industry leader with a strong track record of working with and growing innovative clinical stage companies and has extensive experience managing global drug development and commercialization."

"Omega is pioneering a new class of programmable mRNA therapeutics that have the potential to transform the way we approach difficult-to-treat diseases," said Mr. Boehm. "This is an exciting time for the Company, and I look forward to partnering with this accomplished board of directors and management team and sharing insights as they continue to pave new roads through the discovery and development of epigenomic controllers for patients in need."

Mr. Boehm brings over 30 years of clinical and managerial experience to Omega. He held several senior management positions during his extensive tenure at Novartis Pharma AG and its predecessor, CIBA-Geigy, spanning from 1988 to 2017, most recently as Chief Commercial & Medical Affairs Officer. He was a key figure in the successful establishment of Novartis Oncology. He oversaw the launch and life cycle management of many blockbuster brands in different geographies globally, amongst them Femara, Zometa and Glivec in oncology, as well as Cosentyx and Entresto and the immunology and cardiovascular disease areas. Prior to joining Novartis, he served as unit head at the Psychiatric Hospital in Zwiefalten, Germany. Mr. Boehm serves on the boards of Cellectis SA (Nasdaq: CLLS), Humanigen Inc. (Nasdaq: HGEN), BioCopy, AG (private) and Berlin Cures, AG (private). He holds a medical degree from the University of Ulm in Germany, and a Master of Business Administration from Schiller University, Strasbourg Campus in France. Recently he commenced a Master of Public Health program at the Universities of Basel / Bern / Zurich in Switzerland.

About Omega Therapeutics

Omega Therapeutics, founded by Flagship Pioneering, a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The company's OMEGA Epigenomic Programming platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA medicines, Omega Epigenomic Controllers, target specific epigenomic loci within insulated genomic domains, EpiZips, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases, including alopecia.

For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our product candidate pipeline, including our development of OTX-2002 and other drug candidates and Mr. Boehm's impact on the Company. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; the impact of increased demand for the manufacture of mRNA and LNP based vaccines to treat COVID-19 on our development plans; difficulties manufacturing the novel technology on which our OEC candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contacts

Investor contact: Kevin MurphyArgot Partners212.600.1902[emailprotected]

Media contact: Jason BracoLifeSci Communications646.751.4361[emailprotected]

SOURCE Omega Therapeutics

Go here to see the original:
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors - PR Newswire

Rise In Research And Development Projects In Various Regions Such As East Asia, South Asia Are Expected To Offer An Opportunity Of US $ 0.5 Bn In 2022-2026 Period.

Fact.MR A Market Research and Competitive Intelligence Provider: The global induced pluripotent stem cell (iPSC) market was valued at US $ 1.8 Bn in 2022, and is expected to witness a value of US $ 2.3 Bn by the end of 2026.

Moreover, historically, demand for induced pluripotent stem cells had witnessed a CAGR of 6.6%.

Rise in spending on research and development activities in various sectors such as healthcare industry is expected to drive the adoption of human Ips cell lines in various applications such as personalized medicine and precision.

Moreover, increasing scope of application of human iPSC cell lines in precision medicine and emphasis on therapeutic applications of stem cells are expected to be driving factors of iPSC market during the forecast period.

Surge in government spending and high awareness about stem cell research across various organizations are predicted to impact demand for induced pluripotent stem cells. Rising prevalence of chronic diseases and high adoption of stem cells in their treatment is expected to boost the market growth potential.

For more insights into the Market, Request Brochure of this Report

https://www.factmr.com/connectus/sample?flag=B&rep_id=7298

Besides this, various cells such as neural stem cells, embryonic stem cells umbilical cord stem cells, etc. are anticipated to witness high demand in the U.S. due to surge in popularity of stem cell therapies.

Key Takeaways:

Growth Drivers:

For Comprehensive Insights Ask An Analyst Here

https://www.factmr.com/connectus/sample?flag=AE&rep_id=7298

Key Restraints:

Competitive Landscape:

Many key players in the market are increasing their investments in R&D to provide offerings in stem cell therapies, which are gaining traction for the treatment of various chronic diseases.

For instance:

More Valuable Insights on Induced Pluripotent Stem Cell Market

Get Customization on this Report for Specific Research Solutions

https://www.factmr.com/connectus/sample?flag=RC&rep_id=7298

Explore Fact.MRs Coverage on the Healthcare Domain

Human Umbilical Vein Endothelial Cells (HUVEC) Market - According to Fact.MR, the oncology segment is anticipated to accrue highly lucrative gains to the human umbilical vein endothelial cells (HUVEC) market, attributed to their purported effectiveness in targeting malignant growth. Simultaneously, uptake across tissue culture is also likely to widen in the future.

Cardiac Mapping System Market - The advent of cardiac mapping systems enabled electrophysiologists to target and treat complex arrhythmias more effectively than ever. According to the Centers for Disease Control and Prevention, more than 600,000 people die of heart disease in the United States, every year, making it essential for the medical professionals to take strong awareness initiatives to tell people about the availability of cardiac mapping technology, in a move to control the ever-growing cardiac deaths.

Cardiac Ablation Technologies Market - A surge in atrial fibrillation cases is proving to be a growth generator as cardiac ablation technology is prominently used for its treatment. Revenue across the radiofrequency segment is expected to gather considerable momentum, anticipated to account for over50%of global revenue.

Cardiac Patch Monitor Market - A cardiovascular monitor screen is a gadget that you control to record the electrical movement of your heart (ECG). This gadget is about the size of a pager. Cardiac patch monitors are utilized when you need long haul observing of side effects that happen not exactly day by day.

Cardiac Resynchronization Therapy Market - Newly-released Cardiac Resynchronization Therapy industry analysis report by Fact.MR shows that global sales of Cardiac Resynchronization Therapy in 2021 were held atUS$ 5.7 Bn. With7.9%, the projected market growth during 2022-2032 is expected to be slightly lower than the historical growth. CRT-Defibrillator is expected to be the higher revenue-generating product, accounting for an absolute dollar opportunity of nearlyUS$ 4 Bnduring 2022 2032.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. 80% of Fortune 1000's trusts us in critical decision making. We provide both qualitative and quantitative research, spanning market forecast, market segmentation, competitor analysis, and consumer sentiment analysis.

Contact:

Mahendra SinghUS Sales Office11140Rockville PikeSuite 400Rockville, MD20852United StatesTel: +1 (628) 251-1583E:sales@factmr.com

Follow Us:LinkedIn | Twitter

Continue reading here:
Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR...

Hematopoietic Stem Cells: In living organisms, a specialized system that consist of blood and its progenitors are referred to as the hematopoietic system.

In particular, this system is made up of cells with specialized functions such as the red blood cells (for carrying oxygen to tissues), white blood cells (for immune defense against pathogens, and foreign agents), platelets (for blood clotting), macrophages and lymphocytes (also for immune defense).

However, many of the said blood cells are temporary and need to be replaced with new ones continuously. But fret not because a single cell can solve the problem!

Every day, almost billions of new blood cells are synthesized within the body with each coming from a specific progenitor cell called the hematopoietic stem cell.

How to pronounce Hematopoietic Stem Cells?

What is Hematopoiesis?

The formation of all kinds of blood cells including creation, development, and differentiation of blood cells is commonly known as Hematopoiesis or Haemopoiesis.

All types of blood cells are generated from primitive cells (stem cells) that are pluripotent (they have the potential to develop into all types of blood cells).

Also referred to as hemocytoblasts, hematopoietic cells are the stem cells that give rise to blood cells in hematopoiesis.

Where Does Hematopoiesis Occur?

In a healthy adult, hematopoiesis occurs in the bone marrow and lymphatic tissues, where 1000+ new blood cells (all types) are generated from the hematopoietic stem cells to main the steady-state levels.

Where Are Hematopoietic Stem Cells Found?

They can also be found in the umbilical cord and in the blood from the placenta.

Who Discovered Hematopoietic Stem Cells?

It was long believed that the majority of hematopoiesis occurs during ontogeny (origination and development of organism) and that the mammalian hematopoietic system originated from the yolk sac per se.

Functions of Hematopoietic Cells

As alluded to earlier, blood cells and blood cell components are formed in a process called hematopoiesis.

Coming from the Greek words hemato and poiesis which mean blood and to make respectively, hematopoiesis occurs in the bone marrow and is responsible not only for the synthesis but also the multiplication, and differentiation of blood cells.

Shown below is a diagrammatic illustration of the different blood cell types that hematopoietic cells can give rise to:

Clinical uses of Hematopoietic Stem Cells

The mammalian blood system showcases the equilibrium between the functions of hematopoietic stem cells. Intensive studies have already shown the structures and molecules that control these stem cells, but the exact picture of the underlying molecular mechanisms is still unclear.

Above everything else, it is important to note that such issues are not just of academic interest but can also be relevant in devising future novel methods of diagnosing and treating various diseases associated with cells.

Key References

Read the original post:
Hematopoietic Stem Cells | Hematopoiesis | Properties & Functions

a { color: #fff !important;}@media (min-width: 768px) { #CollapsingNavbar .login.login-fr, #CollapsingNavbar .account.login-fr { padding-left: 0.5rem !important; } #navbar-main nav ul li.nav-item:nth-child(2).active .view-all a:link, #navbar-main nav ul li.nav-item:nth-child(2).active .view-all a:visited, #navbar-main nav ul li.nav-item:nth-child(2).show .view-all a:link, #navbar-main nav ul li.nav-item:nth-child(2).show .view-all a:visited { background-color: #C4161C; } .impact-height { min-height: 300px; }}@media (min-width:992px) { .carousel-indicators { margin-right: 65%; } #block-cbslogin { margin-right: 1rem !important; margin-top: 5px; margin-bottom: -5px; }}@media (min-width: 1200px) { .modal-xl { max-width: 1400px; } .carousel-indicators { margin-right: 60%; }}@media only screen and (max-width: 650px) { .webform-confirmation-modal { width: 90% !important; }}@media (max-width: 767px) { .carousel-indicators { margin-left: 6%; } .carousel { display: table !important; min-height: 360px; } .path-frontpage .embed-responsive-21by9::before { padding-top: 0; } .carousel-item { position: relative !important; padding: 0 6%; }}@media (max-width: 991px) { .ppp-steps-750 { height: 190px; width: 190px; }}.modal-dialog .ppp-steps-compare a,.modal-dialog .ppp-steps-compare p,.modal-dialog .ppp-steps-compare h3,.modal-dialog .ppp-steps-compare li { color: #fff;}.ppp-steps-compare .views-field-field-process { padding-right: 3rem; padding-left: 3rem; padding-top: 2rem; padding-bottom: 2rem;}.ppp-steps-compare .paragraph-id-16025,.ppp-steps-compare:nth-child(1) .views-field-field-process { background: #C4161C; padding-right: 1rem; padding-left: 1rem;}.ppp-steps-compare .paragraph-id-16029,.ppp-steps-compare:nth-child(2) .views-field-field-process { background: #419B96; padding-right: 1rem; padding-left: 1rem;}.img-fluid .media { display: block !important;}.paragraph.paragraph--type-title-text-link-bg-image:before { display: block;}.align-left.media--type-image.media--view-mode-default { padding-right: 2rem;}.align-right.media--type-image.media--view-mode-default { padding-left: 2rem;}.row:before, .row:after{ display: inline-block !important;}.lang-fr .en-only { display: none;}.paragraph--type-content-w-image-link-right img { display: block !important;}.lang-en .fr-only { display: none;}.closeblock .closeblock-button { margin-top: 0 !important; width: 1.4rem; height: 1.4rem; line-height: 1rem; font-size: 1rem;}.progress-marker { z-index: 8 !important;}.menu--employees-menu .nav-link { padding-top: 0; padding-bottom: 0;}.pretty input { width: 23px !important; height: 24px !important;}.carousel-indicators { margin-left: 0; z-index: 4; margin-right: 70%;}.carousel-control-prev, .carousel-control-next { width: 5%;}.carousel-control-prev-icon, .carousel-control-next-icon { width: 4vw; height: 4vw; background-color: #bcbcbc; background-repeat: no-repeat; background-position: 50%; background-size: 3vw; border-radius: 50%}.carousel-indicators li { background-color: #8c8c8c; width: 3vw; min-width: 30px; height: 0.4vw; min-height: 8px;}.carousel-indicators li.active { background-color: #ed1c24;}h2.carousel { font-size: 4.7vw; font-weight: 700 !important;}.paragraph--type-faq.cbs-blood-bg h2,.paragraph--type-faq.cbs-plasma-bg h2,.paragraph--type-faq.cbs-organs-bg h2,.paragraph--type-faq.cbs-stems-bg h2{ color: #fff;}.lang-fr .paragraph--type-designation-tile .paragraph-id-14248 a.btn-location { max-width: 400px;;}.cbs-organs-bg .jump-r a:after,.cbs-organs-bg.jump li:before,.cbs-plasma-bg .jump-r a:after,.cbs-plasma-bg .jump li:before { color: #fff;}#navbar-main .dropdown-menu.show li > span { padding: 0 2rem !important;}.lang-fr #block-secondarynavigation-3 li.nav-item a { padding-right: 6px !important; padding-left: 6px !important;}.edge-only,.explorer-only { display: none;}@supports (-ms-ime-align:auto) { .edge-only { display:block; }}@media all and (-ms-high-contrast:none) { .explorer-only { display: block; }}

See original here:
Canadian Blood Services Stem Cells for Life

City of Hope recently shared significant news at the 24th Annual AIDS Conference about a patient treated in 2019 whose HIV has been in remission. The man had been living with HIV for 31 years before coming to City of Hope with another grave diagnosisacute myeloid leukemia.One of the best hopes for long-term remission of acute myeloid leukemia (AML) is a stem cell transplant, and City of Hope has one of the nations leading transplant programs, having performed more than 17,000 transplants since 1976. In addition, the institution is at the forefront of using transplants to treat older adults with blood cancers, including increasing efficacy and safety in those over 60 and those with comorbidities, like the then 63-year-old City of Hope patient with HIV. The research was presented by Jana K. Dickter, M.D., City of Hope associate clinical professor in the Division of Infectious Diseases.

City of Hope hematologist Ahmed Aribi, M.D., assistant professor in the Division of Leukemia, prepared the patient for an allogeneic blood stem cell transplant with a chemotherapy-based, reduced-intensity regimen developed for treatment of older patients with blood cancers. Reduced-intensity chemotherapy makes the transplant more tolerable for older patients and reduces the potential for transplant-related complications from the procedure.

Aribi and his team worked with City of Hopes Unrelated Donor BMT Program directed by Monzr M. Al Malki, M.D. to find a donor who was a perfect match for the patient and had the rare genetic mutation, homozygous CCR5 Delta 32, which is found in just 1 to 2% of the general population.

People who have this mutation have a resistance to acquiring HIV. CCR5 is a receptor on CD4+ immune cells, and most strains of HIV use that receptor to enter and attack the immune system. But the CCR5 mutation blocks that pathway, which stops HIV from replicating.

After this successful transplant for both AML and HIV, the patient has been in remission for HIV since stopping ART in March 2021. While this outcome has happened in three other patients, the City of Hope patient was both the oldest to undergo a transplant with HIV and leukemia and go into remission for both. He had also lived with HIV the longest 31 years.

The City of Hope patient is another major advancement. It demonstrates that research and clinical care developed and led at City of Hope are changing the meaning of an HIV diagnosis for patients across the United States and the world, said John Zaia, M.D., director of City of Hopes Center for Gene Therapy, Aaron D. Miller and Edith Miller Chair for Gene Therapy and a leader in HIV research. City of Hope remains at the forefront of clinical research that changes peoples lives for the better.

When I was diagnosed with HIV in 1988, like many others, I thought it was a death sentence. I never thought I would live to see the day that I no longer have HIV. City of Hope made that possible, and I am beyond grateful. The City of Hope patient

The story above is one significant example of several important advances being made at City of Hope in the care of people with HIV. When many centers still treated patients with low-intensity, noncurative treatment approaches for HIV-related lymphoma, City of Hope challenged that paradigm by demonstrating that autologous transplantation could be used to cure patients who would otherwise die.

More recently, City of Hope is leveraging its leadership in CAR T cell therapya groundbreaking treatment currently used to rally the bodys natural defenses against cancer and exploring its potential in tandem with another advance, City of Hopes vaccine for cytomegalovirus (CMV).

In a proof-of-concept study, funded by theCalifornia Institute for Regenerative Medicine, lab models demonstrated that the combination therapy could recognize and eliminate HIV without serious toxicity to cells in the virus host. In cultured human cells, the CAR T cells killed cells tagged with the gp120 protein, and kept killing them, without significant signs of risking damage to healthy cells. In a mouse model for HIV/AIDS, high doses of the dual-action CAR T cells followed by the CMV vaccine were successful in controlling HIV, and even nestled into the bone marrow, indicating potential for treatment to keep working over the long term.

In addition to achieving breakthrough outcomes in cancer and HIV, City of Hope has been recognized as the seventh "Best Hospital" for cancer in the nation according to U.S. News & World Report's 2022-23 Best Hospitals: Specialty Ranking. This marks the first time the cancer treatment center has cracked the top 10 of the U.S. News & World Report annual rankings and the 16th consecutive year it has been distinguished as one of the nation's elite cancer hospitals. It was also rated as high performing in four cancer surgery specialties: lung, colon, prostate and ovarian cancers.

See the article here:
From optimized stem cell transplants to CAR T cell therapy: Advancing options for cancer, HIV and more - City of Hope

A litle girl who thought she was winning a long battle against an aggressive form of cancer has died, leaving her family devastated. Libby Jones, 11, had neuroblastoma and it was throughout her body from her jaw to her knees.

She bravely underwent months of surgery, radiotherapy, chemotherapy and even a stem cell transplant that - doctors thought - was working to beat the cancer. The treatment included a seven-hour operation to remove the main tumour from her ribs, CoventryLive reported.

In June this year, the Nuneaton family received the news they had prayed and waited for with medics suggesting she would be clear of cancer by Christmas. But their joy was short lived and turned to devastation when, just weeks later on August 11, Libby became unwell and was taken back into hospital.

READ MORE: Violence flares during India v Pakistan cricket street celebrations in Belgrave, Leicester

Her family received the heartbreaking news that the cancer was back. It had moved to her brain and was even more aggressive than before.

Days later they were told the cancer was incurable and no further treatments were available. Libby returned home on August 18 and passed away on August 24.

A GoFundMe page has been set up to give the former Milby Primary School pupil the 'send off she deserves'. On the page, entitled 'Please help Libby have the send off she deserves', it says: "We desperately want to give Libby the send-off she deserves and Mara, Megan and Logan deserve this.

"If you can find it within your heart to be able to donate even 1 it really would make a difference."

So far, almost 2,500 has been raised in memory of Libby. Arrangements have been made for her funeral and it will take place on Monday, September 5, at 9.30am at the Heart of England Crematorium in Eastboro Way, Nuneaton.

The funeral procession will pass Higham Lane School at around 9.10am and then Milby Primary School at 9.20am. Tributes have been paid to Libby online. One person wrote: "Sad news - heaven has a beautiful angel."

Another wrote: "Such sad news - fly high angel." To donate to the GoFundMe page click here.

READ NEXT:

Excerpt from:
Devastation over death of schoolgirl, 11, who hoped she was beating cancer - Leicestershire Live

Humans fear death so much that some of us would willingly trade our immortal souls if such a thing exists and become vampires for a chance to keep wandering the world a little longer. You can quench your thirst for vampire lore with the upcoming Vampire Academy series (streaming on Peacock Sept. 15), but in the meantime jellyfish might be teaching us how to live forever without needing to drink the blood of unsuspecting mortals.

Weve known for some time that Turritopsis dohrnii, otherwise known as the immortal jellyfish, was out there living its best life over and over again by intermittently switching between its adult and larval stages. When the stresses of being an adult become too much for it to bear, it simply turns back the clock to become a juvenile and starts the whole process over again. While disease or predation can and does end the life of individual jellies, they dont succumb to the same biological ticking clock as the rest of us.

While weve been able to observe this behavior in immortal jellyfish, so far it has been unclear what biological mechanisms contribute to their everlasting life. Now, scientists from the Department of Biochemistry and Molecular Biology at the University of Oviedo have identified the genes responsible, opening the door to future research. Their findings were published in the Proceedings of the National Academy of Sciences.

Zeroing in on what makes the immortal jellyfish special required a comparison of their genome with that of a close relative. Scientists compared their DNA with that of Turritopsis rubra, a jellyfish which is similar to the immortal jelly but, importantly, cannot regenerate. By comparing the genomes, they were able to identify specific sequences which the immortal jelly uses to revert from its adult medusa stage back to its larval stage, a process known as transdifferentiation.

The comparison revealed genes involved in DNA replication and repair, telomere maintenance, stem cell production, communication between cells, and reduction of the oxidative cellular environment, according to a press release from the University of Oviedo. All of those processes are associated with the healthy, or unhealthy, aging of humans.

The findings suggest there isnt one thing which allows immortal jellyfish to avoid the reaper. Instead, aging is akin to a series of locked doors, each of which needs a specific genetic key. Only by having the whole set of keys can you travel backward along the aging corridor. While most animals are strapped to a biological tram which only moves in one direction, their cells becoming what they are destined to be and then remaining that way, immortal jellyfish can coax their cells into becoming whatever they need to be no matter what stage of life they are in.

Researchers were careful to note that there are no immediate applications pertaining to human aging. Dont expect to visit your local department store and find immortal jellyfish face cream or dehydrated polyp powder promising to make you young. However, they did note that a better understanding of how immortal jellyfish control their cellular states could provide an avenue for tackling aging-related diseases.

What we have learned about the immortal jellyfish could lead to extended lifespan and, importantly, higher quality of life in old age, but its unlikely well be able to revert to our prepubescent stages like they do. When you stop to think about it, would you really want to even if you could? Immortality sounds nice, but at what cost?

It's a fan thing

Join SYFY Insider to get access to exclusive videos and interviews, breaking news, sweepstakes, and more!

Sign Up for Free

Original post:
Scientists unlock the key to immortality in jellyfish - Syfy